

RCINJ Liver Tumor Board

This activity is provided by Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School,
Department of Radiology and Department of Pathology.

Interesting Cases Week of August 28, 2019
Rutgers Cancer Institute of New Jersey
195 Little Albany Street 1st Floor Aud. A
New Brunswick NJ 08903
August 28, 2019 7:00am – 8:00am

Cases Presented

Salma Jabbour MD & John Noshier MD

At the conclusion of this activity, participants will be better able to:

- Recognize the key issues in the diagnosis, staging & treatment of neuroendocrine cancers.
- Examine multidisciplinary approach of case management to enhance the improvement of patient care including primary surgical and adjuvant treatments, quality of life, management of treatment-related side effects and standard post-treatment surveillance care.
- Discuss evidence for recommended treatment course.
- Apply novel technology for regional treatment of hepatic malignancies.
- Determine each patient's eligibility for clinical trials when appropriate.

Target Audience: This activity is designed for medical oncologists, surgical oncologists, general surgeons, radiation oncologists, radiologists, gastroenterologists, pathologists, physician assistants, nurses and nurse practitioners.

Accreditation & Designation Statements:

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMAPRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 1 contact hours. (60-minute CH)

Disclosure Declarations

Dr. Salma Jabbour MD & John Noshier MD have no relevant financial relationships to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Dr. Carpizo has disclosed the following relevant financial relationships: Scientific Founder - Z53 Therapeutics. Drs. Jabbour, and Mrs. Librizzi have no relevant financial relationships to disclose.

